Farallon co-chief investment officer Andrew Spokes
Hedge fund slams Exelixis for R&D management, launches proxy fight for board seats (updated)
A hedge fund is looking to refresh Exelixis, proposing three board director nominees and launching a proxy battle that’s scrutinizing the biotech’s R&D blueprint. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
